BTK and susceptibility to pneumonia measurement: A pharmacovigilance study based on the FAERS database revealed that infection-related adverse reactions, such as pneumonia associated with ibrutinib and acalbrutinib, were among the most common safety signals linked to high mortality associated with these two BTK inhibitors (24).